Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Dec;31(6):708-715.
doi: 10.1097/MOP.0000000000000813.

Osteogenesis imperfecta: advancements in genetics and treatment

Vittoria Rossi  1 , Brendan Lee  1   2 , Ronit Marom  1   2
Affiliations
Review

Osteogenesis imperfecta: advancements in genetics and treatment

Vittoria Rossi et al. Curr Opin Pediatr. 2019 Dec.

Abstract

Purpose of review: The purpose of this review is to outline the current understanding of the molecular mechanisms and natural history of osteogenesis imperfecta, and to describe the development of new treatments for this disorder.

Recent findings: The introduction of next-generation sequencing technology has led to better understanding of the genetic cause of osteogenesis imperfecta and enabled cost-effective and timely diagnosis via expanded gene panels and exome or genome sequencing. Clinically, despite genetic heterogeneity, different forms of osteogenesis imperfecta share similar features that include connective tissue and systemic manifestations in addition to bone fragility. Thus, the goals of treatment in osteogenesis imperfecta extend beyond decreasing the risk of fracture, to include the maximization of growth and mobility, and the management of extraskeletal complications. The standard of care in pediatric patients is bisphosphonates therapy. Ongoing preclinical studies in osteogenesis imperfecta mouse models and clinical studies in individuals with osteogenesis imperfecta have been instrumental in the development of new and targeted therapeutic approaches, such as sclerostin inhibition and transforming growth factor-β inhibition.

Summary: Osteogenesis imperfecta is a skeletal dysplasia characterized by bone fragility and extraskeletal manifestations. Better understanding of the mechanisms of osteogenesis imperfecta will enable the development of much needed targeted therapies to improve the outcome in affected individuals.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interests

None.

Figures

Figure 1:
Figure 1:
Pharmacologic interventions in OI and their target within the bone. Anti-resorptive agents include the bisphosphonates that reside in the bone matrix and inhibit osteoclast activity, and denosumab which targets the receptor activator of nuclear factor kappa-B ligand (RANKL that stimulates osteoclast formation and function). Anabolic therapies include teriparatide (a PTH analogue) that is promoting osteoblast differentiation and activity, and sclerostin inhibitory antibodies (Scl-Ab) that increase bone formation via Wnt signaling. TGF beta inhibition is a new approach designed to target the excessive activation of TGF beta signaling within the bone matrix which is thought to contribute to the bone fragility.
See this image and copyright information in PMC

References

    1. Marini JC, Forlino A, Bachinger HP, et al. Osteogenesis imperfecta. Nat Rev Dis Primers. 2017;3:17052. - PubMed
    1. Marom R, Lee YC, Grafe I, Lee B. Pharmacological and biological therapeutic strategies for osteogenesis imperfecta. Am J Med Genet C Semin Med Genet. 2016;172(4):367–83. - PMC - PubMed
    1. Robinson ME, Rauch F. Mendelian bone fragility disorders. Bone. 2019. - PubMed

    2. ** This is an up-to-date summary of the current knowledge on the genetics, phenotype and pathomechanisms of OI and related disorders.

    1. Peddada KV, Sullivan BT, Margalit A, Sponseller PD. Fracture Patterns Differ Between Osteogenesis Imperfecta and Routine Pediatric Fractures. J Pediatr Orthop. 2018;38(4):e207–e12. - PubMed

    2. * This study compared fracture patterns in a cohort of OI patients and controls, and identified OI-specific fracture characteristics that are of diagnostic value.

    1. Lu JT, Campeau PM, Lee BH. Genotype-phenotype correlation--promiscuity in the era of next-generation sequencing. N Engl J Med. 2014;371(7):593–6. - PubMed

Publication types

Substances